 
I5Q-MC -CGAJ Clinical Protocol 
 
 A Phase 3, Long-Term, Open-Label Safety Study of  LY2951742 in Patients with Migraine 
  [STUDY_ID_REMOVED] 
 
Approval Date: 23-Sep -2015 
 
 
I5Q-MC-CGAJ Clinical Protocol Page 1 
LY2951742 Protocol I5Q-MC-CGAJ 
A Phase 3, Long-Term, Open-Label Safety Study of 
LY2951742 in Patients with Migraine 
 
Confidential Information 
The information contained in this document is  confidential and is intended for the use of 
clinical investigators.  It is the property of  Eli Lilly and Company or its subsidiaries and 
should not be copied by or distri buted to persons not involved in the clinical investigation of 
LY2951742, unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries.   
Note to Regulatory Authorities : this document may contai n protected personal data 
and/or commercially confidential information ex empt from public disclosure. Eli Lilly and 
Company requests consultation regarding release/redaction prior to any public release. In 
the United States, this document is subjec t to Freedom of Information Act (FOIA) 
Exemption 4 and may not be reproduced or otherwise disseminated without the written 
approval of Eli Lilly and Company or its subsidiaries.  
LY2951742 
A Phase 3, multisite, 12-month, open-label study to assess the safety of LY2951742 (120 
mg and 240 mg/month) in patients suffering from migraine headaches, with or without aura.  
Eligible patients are to be those wi th episodic or chronic migraine. 
Eli Lilly and Company 
Indianapolis, Indiana USA 46285 
Protocol Electronically Signed and Approv ed by Lilly on date provided below. 
 
  
Approval Date: 23-Sep-2015 GMT
I5Q-MC-CGAJ Clinical Protocol Page 2
LY2951742Table of Contents
Section Page
1. Protocol  Synopsi s................................................................................................................ 8
2. Introduction ...................................................................................................................... 12
2.1. Backgro und.................................................................................................................. 12
2.2. Study  Rati onale ............................................................................................................ 12
3. Object ives and Endpo ints.................................................................................................. 14
4. Study  Design ..................................................................................................................... 16
4.1. Overview of Study  Design ........................................................................................... 16
4.2. End of Trial Definit ion.................................................................................................17
4.3. Scientific Rationale for Study  Design ........................................................................... 18
4.4. Justification for Dose ................................................................................................... 18
4.5. Benefit/Risk Assessment .............................................................................................. 18
5. Study  Popul ation............................................................................................................... 19
5.1. Inclusio n Cri teria.......................................................................................................... 19
5.2. Exclusio n Cri teria........................................................................................................ 20
5.3. Screen Failures ............................................................................................................. 23
5.4. Lifestyle and/or Dietary  Requirements ......................................................................... 23
6. Treatment .......................................................................................................................... 24
6.1. Treatments Administered ............................................................................................. 24
6.1.1. Medical Devices ................................................................................................... 24
6.2. Method of Treatment Assignment ................................................................................ 24
6.2.1. Selection and Timing o f Doses ............................................................................. 24
6.3. Blinding ....................................................................................................................... 25
6.4. Packaging and Labelling .............................................................................................. 25
6.5. Preparati on/Handling/Storage ....................................................................................... 25
6.6. Dose Modificat ion........................................................................................................ 25
6.6.1. Speci al Treatm ent Consi derat ions........................................................................ 25
6.7. Treatment Compliance .................................................................................................25
6.8. Concomitant Therapy ................................................................................................... 25
6.9. Treatment after Study  Com pletion................................................................................ 26
6.9.1. Study  Extensio ns.................................................................................................. 26
6.9.2. Continued Access .................................................................................................26
7. Discontinuati on Cri teria .................................................................................................... 27
7.1. Discontinuati on from Study  Treatm ent......................................................................... 27
7.1.1. Perm anent Discont inuat ion from Study Treatment ............................................... 27
I5Q-MC-CGAJ Clinical Protocol Page 3
LY29517427.1.2. Temporary  Discont inuat ion from Study  Treatm ent............................................... 27
7.1.3. Discontinuati on of  Inadvertent ly Enrolled Patients ............................................... 27
7.1.4. Perm anent Discont inuat ion from th e Study .......................................................... 27
7.1.5. Patients Lost to Follow -Up................................................................................... 28
8. Study  Assessments and Procedures ................................................................................... 29
8.1. Efficacy Assessments ................................................................................................... 29
8.1.1. Primary Efficacy  Assessments ............................................................................. 29
8.1.2. Secondary  Efficacy  Assessments .......................................................................... 29
8.1.2.1. Patient Gl obal Impressi on of Severi ty............................................................. 29
8.1.2.2. Patient Gl obal Impressi on of Improvement ..................................................... 29
8.1.3. Appropriateness of Assessments .......................................................................... 29
8.2. Adverse Events ............................................................................................................ 30
8.2.1. Serious Adverse Events ........................................................................................ 30
8.2.1.1. Suspected Unexpected Serious Adverse React ions.......................................... 31
8.2.1.2. Adverse Event Monitoring with a Systemat ic 
Quest ionnaire .................................................................................................31
8.2.2. Com plaint Handling ............................................................................................. 32
8.3. Treatment of Overdose .................................................................................................32
8.4. Safety Assessments ...................................................................................................... 32
8.4.1. Electrocardiograms .............................................................................................. 32
8.4.2. Vital Signs ........................................................................................................... 32
8.4.3. Laboratory  Tests .................................................................................................. 32
8.4.4. Other Tests ........................................................................................................... 33
8.4.5. Safety Moni toring ................................................................................................ 33
8.5. Pharmacokinet ics......................................................................................................... 33
8.6. Pharmacodynamics ...................................................................................................... 33
8.8. Biomarkers ................................................................................................................... 34
8.8.1. Samples for Immunogenicit y Research .................................................................35
8.9. Heal th Economics ........................................................................................................ 35
9. Statistical Considerations and Data Analysis ..................................................................... 37
9.1. Determinat ion of Sample Size ...................................................................................... 37
9.2. General Statist ical Considerat ions................................................................................ 37
9.3. Treatment Group Comparabilit y................................................................................... 38
9.3.1. Patient Disposi tion............................................................................................... 38
9.3.2. Patient Characteri stics.......................................................................................... 38
9.3.3. Concomitant Therapy ........................................................................................... 38
9.3.4. Treatment Compliance ......................................................................................... 38
CCI
I5Q-MC-CGAJ Clinical Protocol Page 4
LY29517429.4. Primary and Secondary  Analyses ................................................................................. 38
9.4.1. Primary Analyses .................................................................................................38
9.4.2. Secondary  Analyses ............................................................................................. 39
9.4.2.1. Efficacy Analyses ........................................................................................... 39
9.4.3. Terti ary/Exploratory  Analyses .............................................................................. 39
9.5. Other Safet y Analyses .................................................................................................. 39
9.5.1. Immunogenicit y Analyses .................................................................................... 39
9.7. Other Analyses ............................................................................................................. 40
9.7.1. H ealth Outcom es and Economics ......................................................................... 40
9.7.2. Device Analyses ................................................................................................... 40
9.8. Subgroup Analyses ....................................................................................................... 40
9.9. Interim Analyses .......................................................................................................... 41
10. Study  Governance Considerat ions..................................................................................... 42
10.1. Regulatory  and Ethi cal Considerat ions, Including the Informed 
Consent Process ........................................................................................................... 42
10.1.1. Inform ed Consent .................................................................................................42
10.1.2. Ethical Review ..................................................................................................... 42
10.1.3. Regulatory  Considerat ions................................................................................... 42
10.1.4. Invest igator Informat ion....................................................................................... 43
10.1.5. Protocol  Signatures .............................................................................................. 43
10.1.6. Final Report Signature ......................................................................................... 43
10.2. Data Qualit y Assurance ................................................................................................ 43
10.2.1. Data Capture System ............................................................................................ 44
10.3. Study  and Si te Cl osure ................................................................................................
.45
10.3.1. Discontinuati on of  Study  Sites............................................................................. 45
10.3.2. Discontinuati on of  the Study ................................................................................ 45
11. References ........................................................................................................................ 46
CCI
I5Q-MC-CGAJ Clinical Protocol Page 5
LY2951742List of Tables
Table Page
Table CGAJ.1. Objectives and Endpo ints............................................................................... 14
I5Q-MC-CGAJ Clinical Protocol Page 6
LY2951742List of Figures
Figure Page
Figure CGAJ.1. Illustrati on of  study  design for Clinical Protocol I5Q -MC-CGAJ. .................. 16
I5Q-MC-CGAJ Clinical Protocol Page 7
LY2951742List of A ppendices
Appendix Page
Appendix 1. Abbreviat ions and Definit ions........................................................................ 48
Appendix 2. Schedule of Act ivities.................................................................................... 49
Appendix 3. Clinical Laboratory  Tests ............................................................................... 54
Appendix 4. Hepati c Moni toring Tests for Treatment -Emergent Abnormalit y.................... 56
I5Q-MC-CGAJ Clinical Protocol Page 8
LY29517421.Protocol Synopsis
Title of Study:
A Phase 3, Long -Term, Open -Label Safety Study  of LY2951742 in Patients with Migraine .
Rationale: 
Study I5Q-MC -CGAJ (CGAJ) will enable a comprehensive assessment of the safety of LY2951742 for up to 1 year 
in patients suffering from migraine, with or without aura.  
Objective(s)/Endpoints:
Objectives Endpoints
Primary
To evaluate the long-term safety and tolerability of 
LY2951742 (120 or 240 mg/mo nth)in patients 
suffering from migraine, with or without aura, for up to 
1 year of treatment .Analy sisof:
treatment -emergent adverse events ( TEAEs )
discontinuation rates
vital signs and weight
electrocardiograms ( ECGs)
laborato ry measures 
other safety parameters , including suicidality 
using the Columbia Suicide Severity Rating 
Scale (C -SSRS)
Secondary
To characterize the long -term pharmacokinetics and 
pharmacodynamics of LY2951742 .Assessment of serum concentrations of 
LY2951742 to enable a pharmac okinetic 
evaluation.
Assessment of plasma concentrations of 
calcitonin gene -related peptide (CGRP )to 
enable a pharmacodynamic evaluation of 
target engagement of LY2951742.
To characterize the long-term immunogenicity of 
LY2951742.Development and consequences of anti -drug 
antibodies and neutralizing antibodies to 
LY2951 742.
I5Q-MC-CGAJ Clinical Protocol Page 9
LY2951742Objectives Endpoints
To evaluate the long-term effectiveness of LY2951742 
in the prevention of migraine.Mean change from baseline in the n umber of 
migraine headache days;
Mean change from baseline in the number of 
headache days;
Proportio n of patients meeting 50% response 
criteria (reduction of at least 50% in the 
number of migraine headache days);
Mean change from baseline in the frequency 
of medication use for the acute treatment of 
migraines or headaches;
Mean change from baseline in patient’s global 
impression (PGI) of illness as measured by 
PGI-Severity ;
Patient’s global impression of improvement as 
measured by PGI-Improvement
To evaluate the long -term effect of LY2951742 on
health outcomes and quality of life.Mean change from baseline to endpoint in the 
evaluation of the Migraine Disability 
Assessment test ( MIDAS ) total score and 
individual items ;
Mean change from baseline to endpoint in the 
Migraine -Specific Quality of Life 
Questionnaire version 2.1 (MSQ v2.1) tot al 
score and individual domains ;
Change f rom baseline in health care resource 
utilization and employment status
To evaluate safety and residual effectiveness during the 
post-treatment follow -up period.Analy sis of safety parameters  
Time to first loss of response (when patient no 
longer meets 50% response criteria and/or 
starts treatment using migraine prevention 
medication) during the post -treatment follow -
up phase
I5Q-MC-CGAJ Clinical Protocol Page 10
LY2951742Objectives Endpoints
To evaluate patient satisfaction with medication and 
deviceSatisfaction with medication using the Patient 
Satisfaction with Medication Questionnaire -
Modified (PSMQ -M).
Satisfaction with and ease of use of the device
for injection using the Subcutaneous 
Administration Assessment Questionnaire 
(SQAAQ)
To evaluate results with respect to use of the 
autoinjectorInjection -related safety/tolerability and device 
performance with autoinjector exposures
I5Q-MC-CGAJ Clinical Protocol Page 11
LY2951742Summary of Study Design :  
Study CGAJ is a multisite , randomized, open -label trial w ith 3 study  periods in patients diagnosed with episodic or 
chronic migraine headache who are treated with 120 mg /month (with a 240 mg loading dose administered as two 
injections of 120 mg each ) or 240 mg/month of LY2951742 .  Injections of LY2951742 should be self -administered .
Treatment Arms and Duration:   
Two treatment arm s: LY2951742 ( 120mg/month , administered as 1 injection ), and LY2951742 (240 mg /month, 
administered as 2 injections of 120 mg ).  Following a 3-to-45-day screening period, eligible patients will be 
randomized to receive one of two fixed dose s ofLY2951742 for up to 12months during an open -label treatment 
phase , followed by a 4 -month, post -treatment phase in which patients are no longer receiving LY2951742 .
Number of Patients :
The study  will screen an estimated 312potential study participants and enroll approximately 2 50 patients to ensure 
that 100patients with migraine complete the 12 -month treatment phase .
Statistical Analysis:
Effectiveness and safety a nalyses will be conducted using an intent -
to-treat (ITT) population, which is to include all 
patients who receive at least one dose of investigational product .    
Continuous safety and efficacy variables with repeated measures will be analyzed using mixed-model repeated 
measures (MMRM) which will include the fixed categorical effects of treatment, treatment -by-visit interaction,
pooled investigative site, visit, as well as the continuous fixed covariates of baseline andbaseline -by-visit 
interaction .  When appropriate ,an analy sis of variance (ANOVA) or an analy sis of covariance (ANCOVA )model 
with LOCF imputation will be used .  Baseline value will be the last available value from Visit 1 to Visit 2 .  
Categorical safety and efficacy variables with repeated measures will be analyzed using generalized linear mixed 
model (GLIMMIX) in a similar manner as for mean change sabove. Categorical safety variables without repeated 
measures will be analyzed by Cochran -Mantel -Haenszel (CMH) test controlling for pooled investigative site 
(Fisher’s exact tests, if needed) .
Subgroup analyses will be conducted for some of the efficacy and safety measures. No interim analyses are planned 
for this study.  However, an interim analysis may be conducted in support of   regulatory  submissions if necessary.
I5Q-MC-CGAJ Clinical Protocol Page 12
LY29517422.Introduction
2.1. Background
Migraine is a chronic, debilitat ing condit ion found to be one of the top 10causes of disabilit y 
expressed as years lived with disabilit y globally (Vos et al . 2012).  However, one study  estimates 
that only a small fract ion of patients receive prevent ive treatment, although more than 25% of 
migraineurs are in need of prevent ive therapy (Rizzoli 2014).  Despite the availabilit y of 
prevent ive medicat ions for migraine, significant needs remain for new treatm ent opti ons wi th 
improved efficacy and tolerabilit y.
Calcitonin gene -related pepti de(CGRP), a 37 -amino acid neuropeptide , is widely expressed 
throughout the central and peripheral nervous sy stem and acts as a local facilitator of 
inflammatory  processes .  Ca lcitonin gene -related pepti deis implicated in the pathophysio logy of  
migraine and is hypothesized to be invo lved in the release of inflammatory  mediators and the 
transmissio n ofnocicept ive (p ain) informat ion from intracranial  blood vessels to the nervous 
system  (Villal ónand Ol esen 2009). In migraineurs, serum concentrations of CGRP are 
significant ly elevated during migraine attacks (Goadsby  et al . 1990; Goadsby  and Edvinsson 
1993), and infus ion of CGRP to individuals wit h a history  of migraine can trigger migraine 
attacks (Lassen et al. 1998, Lassen et al. 2002). The neutraliz ation of CGRP with antibodies has 
been shown to modulate neurogenic inflammat ion; thus, these ant ibodies may represen t a 
promising pharmaco logicapproach for the preventio n of migraine (Investi gator’s Brochure [IB], 
Secti on 3.1).
LY2951742 is a humanized monoclonal ant ibody  that potently  and selectively binds t o CGRP, 
prevent ing CGRP -mediated bio logical effects (IB, Sec tion 3.1).  To date, m ore than 450 clinical 
trial parti cipants have been exposed to LY2951742 at single doses ranging fro m 1 to 600 mg and 
multiple doses up to 300 mg in 5 clinical trials of LY2951742.  In studies of pat ients with 
migraine ( Studi es I5Q -MC-ART1 [ART -01] and I5Q -MC-CGAB [CGAB]), efficacy data have 
demonstrated that LY2951742 had significant ly greater mean reduction s than placebo in 
migraine headache days and other efficacy  parameters.  Across clinical studies of LY2951742, 
assessment of adver se events (AEs) indicates that LY2951742 has been well tolerated in both 
healt hy subjects and in pat ients with episodi c migraine.  The AEs generally  have been mild to 
moderate in severit y. In two studies of pat ients with migraine, the most frequent ly repo rted AEs 
included inject ion
-site pain, upper respi ratory  tract infect ion, abdo minal pain, dizziness, 
inject ion-site ery thema, rash, hypertensio n, and nasopharyngit is.  Analyses of laboratory  values 
and cardio vascular mo nitoring of the clinical studies have shown no other clinically  important 
changes in tested parameters.
2.2. Study Rationale
Study  I5Q-MC-CGAJ (CGAJ) will enable a comprehensive safet y assessment of LY2951742 in 
both episodic and chronic migraine pat ientsby including those wi th a history  of at least 
4 migraine headache days during a recent 30- day period (Section 5.1)and will build upon 
preliminary evidence of efficacy and safety  from com pleted studi es of LY2951742.  This study  
is intended to provide long-term data that will help support a registration program forpatients 
I5Q-MC-CGAJ Clinical Protocol Page 13
LY2951742with migraine and to provi de data in pat ients who self -inject LY2951742 .  Study  CGA J will 
include 12months on LY29517 42followed by  4 months of post -treatm ent observation to deepen
understanding of the effects of a CGRP ant ibody  in preventing migraines .  
I5Q-MC-CGAJ Clinical Protocol Page 14
LY29517423.Objectives and Endpoints
Table CGAJ .1shows the study  objectives and endpo ints.
Table CGAJ.1. Objectives and Endpoints
Objectives Endpoints
Primary
To evaluate the long-term safety and tolerability of 
LY2951742 (120 or 240 mg/mo nth)in patients suffering 
from migraine, with or without aura, for up to 1 year of 
treatmentAnaly sis of:
treatment -emergent adverse events ( TEAEs )
discontinuation rates
vital signs and weight
electrocardiograms ( ECGs)
laborato ry measures 
other safety parameters, including suicidality 
using the Columbia Suicide Severity Rating 
Scale (C -SSRS)
Secondary
To characterize the long -term pharmacokinetics and 
pharmacodynamics of LY295 1742Assessment of serum concentrations of 
LY2951742 to enable a pharmac okinetic 
evaluation.
Assessment of plasma concentrations of CGRP 
to enable a pharmacodynamic evaluation of 
target engagement of LY2951742
To characterize the long -term immunogenicity of 
LY2951742.Development and consequences of anti-drug 
antibodies and neutralizing antibodies to 
LY29517 42.
To evaluate the long-term effectiveness of LY2951742 
in the prevention of migraineMean change from baseline in the n umber of 
migraine headache days
Mean change from baseline in the number of 
headache days
Proportio n of patients meeting 50% response 
criteria (reduction of at least 50% in the 
number of migraine headache days)
Mean change from baseline in the frequency of 
medicati on use for the acute trea tment of 
migraines or headaches
Mean change from baseline in patient’s global 
impression of illness as measured by PGI -
Severity ;
Patient’s global impression of improvement as 
measured by PGI-Improvement
I5Q-MC-CGAJ Clinical Protocol Page 15
LY2951742Objectives and Endpoints
Objectives (cont.) Endpoints (cont.)
Secondary (cont.)
To evaluate the long -term effect of LY2951742 on
health outcomes and quality of lifeMean change from baseline to endpoint in the 
evaluation of the Migraine Disability 
Assessment test ( MIDAS )total score and 
individual items
Mean change from baseline to endpoint in the 
Migraine -Specific Quality of Life 
Questionnaire version 2.1 (MSQ v2.1) total 
score and individual domains
Change f rom baseline in healthcare resource 
utilization and employment status
To evaluate safety and residual effectiveness during the 
post-treatment follow -up periodAnaly sis of safety parameters  
Time to first loss of response (when patient no 
longer meets 50% response criteria and/or starts 
treatment using migraine prevention 
medication) during the post-treatment follow -
up phase
To evaluate patient satisfaction with medication and 
deviceSatisfaction with medication using the 
PSMQ -M.
Satisfaction (and ease of use) with the device 
for injection using the Subcutaneous 
Administration Assessment Questionnaire 
(SQAAQ)
To evaluate results with respect to use of the autoinjector Injection -related safety/tolerability and device 
performance with autoinjector exposures
I5Q-MC
LY2951742 4.1. O
Study C G
of 120 m
LY2951 7
permitte d
will be a l
Figure C
Figure C
Study P e
informe d
are requi
30 days p
at least 4
The scre e
medical e
(Append
screenin g
-CGAJ Cli n
Overview 
GAJ is a Ph a
mg/month L Y
742 in patie n
d to enroll i n
llowed to se
GAJ.1 illus t
CGAJ.1. 
eriod I:   The
d consent fo r
red to disco n
prior to Visi t
 months pri o
ening visit ( V
evaluation d
ix 2).  Visit 
g assessmen t
nical Prot o
of Stud y
ase 3, multis i
Y2951742 ( w
nts suffering
n Study CG A
lf-inject, th e
trates the st u
Abbreviat i
a Patie n
the fi r
b Tele p
Illustrat i
e study and p
rm (ICF) m u
ntinue all e x
t 2.  Botulin u
or to Visit 2 .
Visit 1) will 
documenting 
1 will be co n
t for the pat i
ocol
4. St u
y Design
ite, randomi
with an initi a
 from migr a
AJ if they pr e
e study will c
udy design. 
ion:  SP = Stu d
nts randomize d
rst injection o n
phone visit. 
ion of stud y
potential ris k
ust be signe d
xcluded med i
um toxin A o
. 
consist of a 
medical hi s
nsidered co m
ient is comp l
udy De s
zed, long-te r
al loading d o
aine, with or 
eviously we r
consist of a m
dy Period. 
d to the 120 m g
nly (Visit 2). 
y design fo r
ks will be e x
d before per fo
ications or m
or B in the h
full clinica l
story, and a p
mplete whe n
leted.  
sign 
rm, open-la b
ose of 240 m
without aur a
re treated w i
mix of offic e
g dose will rec
r Clinical P r
xplained to t h
forming any 
migraine pre v
head or nec k
l assessmen t
physical an d
n the last sc h
bel study to 
mg) and 240 m
a.  Patients w
ith LY2951 7
e visits and t
eive a loading 
rotocol I5Q -
he patient a t
study proce d
vention trea t
k area must b
t, including a
d neurologic a
heduled proc
Pag
assess the s a
mg/month 
will not be 
742.  As pat i
telephone v i
dose of 240 m
-MC-CGAJ.
t Visit 1.  T h
dures.  Pati e
tments at le a
be discontin u
a comprehe n
al examinati
edure of the
ge 16 
afety 
ients 
isits. 
 
mg at 
he 
ents 
ast 
ued 
nsive 
on 
e 

I5Q-MC-CGAJ Clinical Protocol Page 17
LY2951742Study Period II :  If the patient meets all requirements for study eligibilit y, the pati ent will be 
rando mized to treatment with one of two doses of LY2951742 (120 mg or 240 mg) at Visit 2 and 
receive the first dose of LY2951742 at that visit following pretreatment laboratory  tests and 
blood draws. LY2951742 will be administered as subcutaneous inject ionsonce m onthly at the 
dosin g visi ts (Visi t 2, and Visit 4 through Visi t 14) f or a total  of 12 doses. Patients rando mized 
to 120 mgwill receive an init ial loading dose of 240 mg (2 inject ions of 120 m g each) at Visi t 2.  
All injecti ons at subsequent dosing visits will be self-admin istered as a single inject ion of 
120mg.Those randomized to 240 mg LY2951742 will receive two inject ions of 120 m g each at 
Visit 2 and all  subsequent vi sits.  Inject ions will be delivered via prefilled syringe or by  an 
investigat ional autoinjector (when the autoinjector device is available for clinical trial use ).  
Patients (and caregivers) will receive training on the use of the prefilled sy ringe and on the use of 
the autoinjector when switched to the autoinjector.
At Visi t 2(first dose) , the patient mu st rem ain at the study  site for a 30 -minute post-inject ion 
observat ion peri od. Following appropriate training, all subsequent inject ions of LY2951742 will 
be administered by  the patient (or caregiver ).  Injecti ons administered by  the pat ient at Vi sit 4 
and Visit 5 will be done in the office under the supervisio n of site staff; all subsequent inject ions 
will be administered by  the pat ient/caregiver butshoul d be administered unsupervised by the 
clinical staff.  For all o ffice visits, inject ions will occur after all  study  procedures have been 
perform ed.  For all  telephone visit sat whi ch an injecti on is scheduled to occur , self-inject ions 
must occur on the same day  asthe scheduled visit, prior to the start of visit procedures .  
Unscheduled office visits ar e allowed for safet y reasons, assistance with inject ion administration, 
or to supply  new study  drug if needed. If a potentially clinically significant AE is reported by  
the pati ent during a telephone visit, the patient should be brought in for appropriate assessment at 
an unscheduled office visit.
At Visit 2 and all mo nthly visits, invest igators will ask patients about the frequency o f headache 
and migraine headaches experienced in the past 30 day s as well as frequency of medicat ion use 
for migraine or he adache.  In order to aid recall when answering these quest ions, pati ents will be 
trained to keep track of their migraine and headache day s as well as their medicat ion use days 
using the tracking method of their choice during the study  and will  be reminded that the si te staff 
will be asking these quest ions at each visit.  
If a patient discontinues early for any reason during the open -label treatment phase , the pati ent 
shoul d enter the post -treatm ent follow-up period (Study  Period III) ; in such cases, patien ts will  
be encouraged to complete the fo llow-up peri od to assess safet y. 
Study Period III:  During thi s 4-month follow-up peri od, patients will no longer receive 
investigat ional product.  However, patients will cont inue to t rack their headache informat ion.
Site visits are every 2 mo nths.
4.2. End of Trial Definition
End of the trialis the date of the last visit or last scheduled procedure shown in the Schedule of 
Activities(Appendix 2 )for the l ast patient.
I5Q-MC-CGAJ Clinical Protocol Page 18
LY29517424.3. Scientific Rationale for Study Design
The l ength of the open -label treatm ent phase (12 mo nths) is considered an appropriate duration 
to assess the longer -term safety  ofa migraine prevent ion medicat ion and is consistent with 
regul atory  feedback.  A 4-month post -treatm ent follow-up phase is included to evaluate patient 
safet y during wash -out of LY2951742 .  This allows for a total of 5months ofobservat ion from 
the time o f last inject ion of LY2951742.   A 5-month post -treatm ent observat ion peri od allows 
for a wash -out of approximately 5 eliminat ion half -lives of LY2951742 and shoul d decrease 
LY2951742 serum concentrations by approximately 97% during this time .
4.4. Justificatio nfor Dose 
Doses of 120 mg and 240 m g administered once monthly  were selected primarily on the basis of 
clinical efficacy  and pharmacokinet ic/pharmacodynamic data fro m the Phase 2 dose -ranging 
study .  Results fro m the Phase 2 dose-ranging study indicate that 120 mg was statistically 
significant ly superi or to pl acebo at the l ast 28 -day period of the 3 -month treatm ent phase in 
mean change in migraine headache days, as well as other measures of efficacy and qualit y of life. 
The use of a loading dose for the 120 mg arm, and the inclusio n of a 240 mg treatment arm, is 
based on the finding that a higher dose than 120 mg achieved statist ically significant separation 
from placebo as early  as Month 1. Theplanned doses of 120 mg and 2 40 m g LY2951742 for 
Study  CGAJ also are being studied in three pivotal efficacy studies of LY2951742; two of these 
studi es are in pati ents wi th episodi c migraine, and one is in pat ients with chronic migraine.
4.5. Benefit/Risk Assessment
More informat ion about the known and expected benefits, risks, serious adverse events (SAEs) 
and reasonably ant icipated adverse events (AEs) of LY2951742 are to be found in th e 
Invest igator’s Brochure (IB).
I5Q-MC-CGAJ Clinical Protocol Page 19
LY29517425.Study  Population
All patients must meet the fo llowing select ion criteria.  Eligibilit y of patients for study  
enrollment will be based on the results of a screening medical history, physical examinat ion, 
neuro logical examinati on, clinical laboratory  tests, electrocardi ograms ( ECG s), and migraine 
history  during screening, as de scribed in the Inclusio n and Exclusio n Cri teria secti onsof this 
protocol .  The nature of any co morbid condi tions present at the time of the physical examinat ion 
and any  preexist ing condit ions must be documented.   Individuals who do not meet the criteria f or 
participat ion in this study  (screen failure) for specific reasons as outlined maybe considered for 
rescreen ing once, with approval fro m Eli Lilly  and Com pany (Lilly )Medical ( Secti on5.3).
Study  parti cipants shoul d be instructed not to donate blood or blood products during the study or 
for 5 m onths f ollowing the last administration of LY2951742 .
Prospective approval o f protoc ol deviati ons to recrui tment and enro llment criteria, also known as 
protocol  waivers or exempt ions, are not permitted.
5.1. Inclusion Criteria
Patients are eligible to be included in the study  only  if they  meet allof the f ollowing criteria :
Patient and Diseas e Characteristics
[1] Patients are 18 to 65 y ears of age (inclusive )at the time of screening .
[2] Have a diagnosis of migraine as defined by  Internati onal Headache Soci ety 
(IHS) International Classificat ion of Headache Disorders (ICHD) -3 beta 
guidelines (1.1, 1.2, or 1.3 ) (ICHD -3 2013) , with a history  of migraine 
headaches of at least 1 y ear pri or to Visit 1 , and migraine onset prior to age 
50.
[3] Prior to Vi sit 1, a history  of 4 or m ore mi graine headache days per m onth on 
average forthe past 3 months .
[4] Prior to Vi sit 1, a history  of at least 1 headache -free day  per m onth for the past 
3 months. 
Informed Consent and Patient Agreements
[5] Are able and willing to give signed informed consent.
[6] Are reliable and willing to fo llow study  procedures, i ncluding all fo llow-up 
visits.
[7] Women of child -bearing potenti almust test negative for pregnancy  at the time 
of enro llment based on a serum pregnancy test .
I5Q-MC-CGAJ Clinical Protocol Page 20
LY2951742[8] All patients, male and female, must agree to use a reliable method of birth 
control  during the study as well as for 5 months after the last dose of 
investigat ional product. Acceptable methods of birth control for this study 
include: oral contraceptive s; implantable contraceptive s;injectable 
contraceptive s; a contraceptive patch; barrier m ethods such as diaphragms 
with contracepti ve jelly, cervical caps wit h contraceptive jelly, condo ms with 
contraceptive foam, or intrauterine devices; a partner with vasectomy. Birth 
control  is not requi red if the f emale isinfertile due to surgical steriliza tion (at 
least 6 weeks after surgical bilateral oophorectomy , hysterectomy ,or at least 6 
weeks after tubal  ligat ion) confirmed by medical history , or m enopause.  
Menopause is defined as spontaneous amenorrhea for at least 12 months not 
induced by  a medica l condit ion, or spontaneous amenorrhea of 6 -12 m onths 
and a fo llicle st imulating hormone level >40 mIU/mL.
[9] Agree not to post any  personal medical data related to the study  or 
inform ation related to the study  on any websi te or soci al media si te (for 
example, Facebook, Twitter, LinkedIn, Google+ , etc.) until the entire trial has 
completed.
5.2. Exclusion Criteria
Patients will  be excluded from  study  enro llment if they meet any o f the following cri teria at
screening:
Prior/Concurrent Clinical Trial Experience
[10] Are current ly enrolled in any other c linical trial invo lving any invest igational
product or any  other ty pe of medical research judged not to be scient ifically or 
medically co mpat ible with this study.
[11] H ave part icipated within the last 30 day s or wi thin 5 half -lives (whichever is 
longer) in a clinical trial invo lving an invest igational product.  If the 
investigat ional product’s half- life is not known, 6 mo nths should have passed 
prior to Visit 1.
[12] Current use or prior exposure to LY2951742 or ano ther CGRP antibody , 
including those who have previously completed or withdrawn from this study  
or any  other study  invest igating a CGRP antibody .
Prior/Concomitant Therapy
[13]Patients who are taking , or are expected to take, therapeuti c ant ibodies during 
the course of the study  (for example, adalimumab, infliximab, trastuzumab, 
bevacizumab, etc.).  Prior use of therapeutic ant ibodies, other than antibodies 
to CGRP or i ts receptor, is allowed ifthat use was more than 12 m onths prior 
to Visit 2.
[14]Known hypersensit ivity to multip le drugs, m onoclonal  antibodies or other 
therapeuti c proteins, or to LY2951742 .
I5Q-MC-CGAJ Clinical Protocol Page 21
LY2951742[15]Are current ly receiving medicat ion or other treatments for the prevent ion of 
migraine headaches.  Patients must have discont inued such treatment at least 
30 day s prior to Vi sit 2.  Botulinum  toxin A and B that has been administered 
in the head or neck area must be di scont inued at least 4 months prior to 
Visit 2.
[16]Failure to respond to 3or more adequately dosed migraine prevent ive 
treatm ents fro m different classes (that is, maximum tolerated dose for at least 
2 months). Failure to respond due to tolera bility issues is not considered a 
treatm ent failure.  M igraine prevent ivetreatm ents are defined as Level A and 
Level B in Table 1 of the American Academy of Neurology ’s Evidence -based 
Guidelines Update:  Pharmaco logic Treatm ent for Episodi c Migraine 
Preve ntion in Adults (Silberstein et al. 2012 )as well as botulinum toxin A or 
B.
Diagnostics Assessments
[17] History  of persistent daily  headache, cl uster headache ,ormigraine subt ypes 
including hemiplegic (sporadic or familial) migraine, ophthalmoplegic 
migraine, and migraine with brainstem  aura (basilar -type migraine) defined by 
IHS ICHD -3 beta.
[18] History  of headache other than migraine, tensio n type headache, or medicat ion 
overuse headache, as defined by IHS ICHD -3 beta within 3 mo nths prior to 
rando mization.  
[19]History  of head or neck injury  within 6 m onths prior to Vi sit 1.
[20] Patients wi th a history  of traum atic head injury associated with significant 
change in the qualit y or frequency of their headaches should be excluded.
Medical Conditions
[21] Have ECGs showing abnormalit ies compatible wit h acute cardiovascular 
events and/or serious cardiovascular risk, including but not limited to a 
corrected QT (QTcB [Bazett's] )interval > 470 m sec for wom en and >450 for 
men, or h ave had my ocardial  infarct ion, unstable angina, percutaneous 
coronary  intervent ion, coronary  artery  bypass graft, stroke, or deep vein 
thrombosis/pulmo nary embo lism wit hin 6 months of screening, or have 
planned cardio vascular surgery or percutaneous coronary  angi oplasty .
[22] Patients with a body  mass index ≥40 kg/m2
[23] Any liver tests outside the normal range at Visit 1 that are clinically 
significant. Alanine aminotransferase (ALT) >2X upper limit of norma l 
(ULN), ortotal bilirubin level (TBL) >1.5X ULN, or alkaline phosphatas e 
(ALP) >2X ULN must be discussed and judged not clinically significant by  
Lilly Medical prior to enrollment. 
I5Q-MC-CGAJ Clinical Protocol Page 22
LY2951742[24] Evidence of significant active or unstable psychiatric disease by medical 
history , such as bipo lar disorder, schizophrenia, personalit y disorders, or other 
serious m ood or anxiet y disorders. Note : Patients with major depressive 
disorder or generalized anxiet y disorder whose disease state is considered 
stable and expected to remain stable throughout th e course of the study , in the 
opinio n of the invest igator, may be considered for inclusio n if they are not on 
excluded medicat ions.
[25]Patients who, in the clinician’s judgment are actively  suicidal  and therefore 
deem ed to be at si gnificant ri sk for sui cide, or those who have answered “yes”
to either Question 4 (Act ive Suicidal Ideat ion with Som e Intent to Act, 
Without Specific Plan) or Question 5 (Act ive Suicidal Ideation wit h Specific 
Plan and Intent) on the “Suicidal  Ideat ion”portion of  the Columbia -Suicide 
Severit y Rating Scale ( C-SSRS ), or answer “yes”to any  of the sui cide-related 
behaviors (actual attempt, interrupted attempt, aborted attempt, preparatory  
act or behavior) on the “Suicidal Behavior” portion of the C –SSRS; and the 
ideat ion or behavior occurred within the past month.
[26] Women who are pregnant or nursing.
[27] Patients who have used opio ids or barbiturate containing analgesic > 3Xper 
month for the treatment of pain in more than 2of the past 6 m onths (opi oid 
administration in an emergency  setti ng may be an exception).
[28]History  of drug or al coho l abuse/dependence wit hin 1 y ear pri or to Vi sit 1 
(excessive or compulsive use as judged by  the Investi gator), or currently using 
drugs of abuse (including opio ids, barbiturates and marijuana), or any 
prescribed or over- the-counter medicat ion in a manner that the Investigator 
considers indicat ive o f abuse/dependence.
[29]Have a posit ive urine drug screen for any substances of abuse at Visit 1.  
Note:  A single retest is allowed if the urine drug screen is posi tive for any  
prescribed substance or if, in the judgment of the investigator, there is an 
acceptable explanat ion for the posit ive result.  The results of the retest must be 
negat ive at or pri or to Vi sit 2.
[30] Have a history  or presence of any  other medical  illness including but not 
limited to any  autoimmune disorder, cardiovascular, hepatic, respiratory , 
hematol ogical, endocrine, psychiatric or neurological disease, or any  clinically  
significant laboratory  abno rmality, that in the judgment of the investigator, 
indicates a medical problem that would preclude study  parti cipat ion.  
Other Exclusions
[31] In the opinion o f the invest igator have other issues which would interfere with 
compliance wi th the study  requi rements and com pletion of  evaluat ions 
requi red for thi s study .
I5Q-MC-CGAJ Clinical Protocol Page 23
LY2951742[32] Are invest igator site personnel directly affiliated wit h this study  and/or thei r 
immediate families.  Immediate family is defined as a spouse, parent, child, or 
sibling, whether bio logicalor legally adopted .
[33] Are Lilly  empl oyees. 
5.3. Screen Failures
Individuals who do not meet the criteria for participation in this study  (screen failure) m ay be 
considered for rescreening once, with approval from Lilly Medical, for only the fo llowing 
criteria:
Inclusio n criterion 1. If patients are less than age 18 at the time o f informed 
consent, they  may be rescreened if they  reach age 18 during the study  enrollment 
period.
Inclusion criterion 7
Exclusio n criterion 11
Exclusio n criterion 13
Exclusio n criterion 15
Exclusio n criterion 26
Patients using a concomitant medicat ion that requires a stable dose for a specific durat ion prior 
to Visit 2 may  be rescreened if addit ional time is needed to meet the duration requirement.
If rescreening is performed, the individual must sign a new ICF and will be assigned a new 
ident ificat ion number.
5.4. Lifestyle and/or Dietary Requirements
No changes in lifestyle or dietary  requi rements are requi red during the study .However, patients 
must be in a fast ing state for collect ion of laboratory samples at selected visit s specified in 
Appendix 2 .
I5Q-MC-CGAJ Clinical Protocol Page 24
LY29517426.Treatment
6.1. Treatments Administered
All patients will receive injections of LY2951742 at doses of 120 or 240 mg administered once 
monthlyfor up to 12monthsduring the treatment p hase ( Secti on 4.1; Appendix 2 ).  Patients 
rando mized to the 120 mg dose of LY2951742 will receive an init ial loading dose of 240 mg 
(2inject ions of 120 m g each) at Visit 2 and 1 injection of 120 m g at each subsequent dos ing 
visit.  Patients randomized to the 240 mg dose will receive 2 inject ionsof 120 m g LY2951742 at 
each dosing visit.  
Possible inject ion sites include the abdo men, thi gh, and upper arm .  Buttocks may  also be used, 
if needed .  If patients are unable to s elf-inject, they may  receive assistance from a caregiver (such 
as a family member).  
The invest igator or his/her designee is responsible for the fo llowing:
training patients and caregivers on the care and use of the prefilled sy ringe and the 
investigat ional autoinjector
verifying that instructions are fo llowed properly
maintaining accurate records of investigational product dispensing
at the end of the study  returning all unused medication to Lilly ,or its desi gnee ,
unless the sponsor and sites have agreed all unused medicat ion is to be destroyed 
by the site, as allowed by local law .
6.1.1. Medical Devices
The m anufactured medical devices provid ed for use in the study area disposable m anual 
prefilled syringe and, at som e point du ring the study, an autoinjector .  An invest igational 
autoinjector device willbe provi dedduring the study when i t becom es available .
6.2. Method of Treatment Assignment
Patients who m eet all cri teria for enrollment will be randomized to one of two dose groups at
Visit 2.  Assignment to treatment groups w ill be determined by a computer -generated random 
sequence using an interactive web -response system (IWRS).   The IWRS will be used to assi gn
open -label invest igational product to each patient. Site person nel will confirm that they  have 
located the correct ly assigned package by entering the confirmat ion number found on the
package into the IWRS.
To achieve between -group com parabilit y for site factor, the randomizat ion will be stratified by  
site.
6.2.1. Selection and Timing of Doses
The actual  time of all dose administrations will be recorded in the pati
ent’s electroni c case report 
form (eCRF).
I5Q-MC-CGAJ Clinical Protocol Page 25 
LY2951742 6.3. Blinding 
Not applicable. 
6.4. Packaging and Labelling 
LY2951742 will be supplied as an injectable solution in 1-mL, single-dose, prefilled, disposable 
manual syringes with study specific labels.  Each  syringe of LY2951742 is designed to deliver 
LY2951742 120 mg.  Syringes will be supplied in cartons, with th e appropriate quantity of 
syringes specific to the planned dispensing sc hedule of the investigational product.  LY2951742 
will be supplied in the investigational autoinjector  when the autoinjector becomes available.   
Clinical trial materials, includi ng devices, will be labeled accord ing to the country’s regulatory 
requirements.  
6.5. Preparation/Handling/Storage 
Investigational product will be ship ped (as prefilled syringes or auto injectors) to sites using cold 
chain transportation.  Study drug must be stable and stored in a refrigerator  at 2ºC to 8ºC (35.6ºF 
to 46.4ºF).  
Approximately 30 minutes prior to administration, the syringe should be removed from the 
storage area and allowed to e quilibrate at ambient conditions.  The drug product should be kept 
away from direct exposure to bri ght light (such as sunlight) and hot  surfaces until administration. 
6.6. Dose Modification 
Dose modifications are not permitted in this study.  
6.6.1. Special Treatment Considerations 
During the post-treatment follow-up period, pa tients will not receive LY2951742.  One month 
after Visit 15 (2 months after la st dose), if clinically warranted due to a worsening of symptoms, 
patients may start migraine preven tion medications at the discretion of the investigator.  The list 
of allowed preventive medica tions is provided separately. 
6.7. Treatment Compliance 
Investigators will be required  to document the administra tion of LY2951742 in the eCRF. 
LY2951742 must be administered as indicat ed in the Schedule of Activities ( Appendix 2) .  If the 
patient is unable to comply w ith injections in the allowed window, the situation should be 
discussed with Lilly to determine if the patient may continue. 
6.8. Concomitant Therapy 
The list of medications allowed or not allowed during the study can be found in the concomitant 
medications study tool.  The concom itant use of acute medications to treat migraine is allowed, 
with some limitations.  Any changes in the lis t of allowed/not allowed medications will be 
communicated to investigators and will not constitute a protocol amendment. 
I5Q-MC-CGAJ Clinical Protocol Page 26
LY29517426.9. Treatment after Study Completion
6.9.1. Study Extensions
Not applicable.
6.9.2. Continued Access
Invest igational product will not be m ade available to patients after concl usion of thisstudy .
I5Q-MC-CGAJ Clinical Protocol Page 27
LY29517427.Discontinuation Criteria
Patients who discont inue the stu dy or invest igational product during open -label treatment (Study  
Period II) will proceed immediately to Study  Period III.
7.1. Discontinuation from Study Treatment
7.1.1. Permanent Discontinuation from Study Treatment
Discontinuati on of  the invest igational product for abnormal liver tests should be considered by 
the invest igator when a pat ient meets one of the fo llowing condi tions af ter consul tation wi th the 
Lilly designated medical mo nitor:
ALT or aspartate aminotransf erase (AST) >8XULN
ALT or AST >5X ULN for more than 2 weeks
ALT or AST >3X ULN and TBL >2X ULN or prothrombin t ime >1.5X ULN
ALT or AST >3X ULN with the appearance of fat igue, nausea, vo miting, right 
upper -quadrant pain or tenderness, fever, rash, and/or e osinophilia (>5%)
ALP >3X ULN
ALP >2.5X ULN and TBL >2X ULN
ALP >2.5X ULN with the appearance of fatigue, nausea, vo miting, right quadrant 
pain or tenderness, fever, rash, and/or eosinophilia (>5%)
Patients who discont inue the invest igational product early will have end -of-therapy procedures 
perform ed as shown in the Schedule of Act ivities(Appendix 2 )and are requested to proceed into 
the post -treatment phase .
7.1.2. Temporary Discontinuation from Study Treatment 
Not applicable.
7.1.3. Discontinuation of Inadvertently Enrolled Patients
If the sponsor or invest igator ident ify a pat ient who did not meet enrollment criteria and was 
inadvertent ly enro lled, a discuss ion must occur between the sponsor clinical research 
physician/clinical research scient ist (CRP /CRS )and the investigator to determine if the pat ient 
may cont inue in the study.  If both agree it is medically appropriate to continue, the invest igator 
must obtain documented approval fro m the sponsor CRP /CRS to allow the inadvertent ly enro lled 
patient to co ntinue in the study  with or wi thout treatm ent wi th invest igational product.
7.1.4. Permanent Discontinuation from the Study
Some possible reasons that may  lead to perm anent di scontinuat ion include:
I5Q-MC-CGAJ Clinical Protocol Page 28
LY2951742Enrollment in any other clinical trial invo lving an investigation al product or enrollment in 
any other ty pe of medical research judged not to be scient ifically or medically co mpat ible 
with this study
Participation in the study  needs to be stopped for medical, safet y, regul atory , or other 
reasons consistent with applicab le laws, regulations, and good clinical pract ice (GCP)
Invest igator Decisio n
othe invest igator decides that the patient should be discontinued from the study
oif the pat ient, for any  reason, requi res treatm ent with another therapeutic agent that 
has been dem onstrated to be effect ive for the study indication (preventi on of  
migraine) during Study  Period II (open -label treatment) ,discont inuat ion from the 
study  occurs pri or to introducti on of  the new agent
Subject Decisio n
othe patient asks to be wi thdrawn from  the study
Patients who discont inue the study early will have end -of-study  procedures perform ed as shown 
in the Schedule of Act ivities(Appendix 2 ) and are requested to proceed into the post- treatm ent 
phase.
7.1.5. Patients Lost to Follow -Up
A pat ient willbe considered lost to fo llow-up if he or she repeatedly  fails to return for scheduled 
visits and is unable to be con tacted by  the study  site.  Site personnel are expected to make 
diligent attempts to contact patients who fail to return for a scheduled visit or were otherwise 
unable to be fo llowed up by  the si te.
I5Q-MC-CGAJ Clinical Protocol Page 29
LY29517428.Study  Assessments and Procedures
Appendix 2 lists the Schedule of Act ivities, with the study procedures and their timing (including 
tolerance limit s for timing).
Appendix 3 lists the laboratory tests that wi ll be perform ed for this study .
Appendix 4 lists the tests that may be obtained in the event of a treatment -emergent hepatic 
abnorm ality.
Unless otherwise stated in the subsect ions below, all samples co llected for specified laboratory
tests will be destroy ed wi thin 60 days of receipt of confirmed test results.  Certain samples may 
be retained for a longer period, if necessary, to comply wit h applicable laws, regulat ions, or 
laboratory  certificati on standards.
8.1. Efficacy Assessments
8.1.1. Prima ry Efficacy Assessments
Not applicable.
8.1.2. Secondary Efficacy Assessments
As thi s is an uncontrolled study , all efficacy measures represent measures of treatment 
effect iveness or health outcomes.  Migraine and headache frequency as well as abortive 
medicat ionuse will  be collected by  direct questi oning by the invest igator or desi gnated si te 
personnel .In addit ion, the fo llowing s cales will be used for secondary  efficacy  assessments as
summarized below. 
8.1.2.1. Patient Global Impression of Severity
The Pati ent Gl obal Impressio n of Severit y (PGI -S) scale ( Guy 1976) is a pati ent-rated instrument 
that measures baseline illness severit y.  The PGI -S includes a range of possible responses, fro m 1 
(“normal, not at all ill”) to 7 (“extremely ill”).
8.1.2.2. Patient Global Impression o f Improvement
The Pati ent Gl obal Impressi on of Improvement (PGI -I) scale ( Guy 1976) i s a patient -rated
instrum ent that m easures the improvement of the patient’s symptoms.  It is a 7 -point scale in 
which a score of 1 indicates that the patient is “very  muchbetter ,” a score of 4 indicates that the 
patient has experienced “no change,” and a score of 7 indicates that the patient is “very  much 
worse.”
8.1.3. Appropriateness of Assessments
All efficacy and safet y assessments have been well documented and are generally  regarded as
reliable, accurate, and relevant in this pat ient population .  Thi s includes healt h outcom es 
measures considered to be appropriate for evaluat ing changes in qualit y of life, global 
funct ioning, and disabilit y (Section 8.9).
I5Q-MC-CGAJ Clinical Protocol Page 30
LY29517428.2. Adverse Events
Invest igators are responsible for monitoring the safety of pat ients who have entered this study  
and for al erting Lilly  or its designee to any  event that seems unusual, even if this event may be 
considered an unant icipated benefit to the patient.
The invest igator is responsible for the appropriate medical care of pat ients during the study.
Invest igators must document their review of each laboratory  safety  report.
The invest igator remains responsible for fo llowing, through an appropriate health care option, 
AEs that are serious or otherwise medically important, considered related to the invest igational 
product , invest igational device, or the study , or that ca used the patient to discont inue the 
investigat ional product before complet ing the study.  The pat ient shoul d be fo llowed unt il the 
event resolves, stabilizes with appropriate diagnostic evaluat ion, or i s reasonably explained.  The 
frequency  of follow-up ev aluations of  the AE is l eft to the discretion of the invest igator.
Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to 
establish treatment effect.
After the ICF is signed, study  site personnel will record via eCRF the occurrence and nature of 
each patient’s pre-exist ing condit ion(s), including clinically significant signs and symptoms of 
the disease under treatment in the study .  In addi tion, si te personnel will record via eCRF any 
change in the condit ion(s)and any  new condi tion(s)asAEs. Invest igators should record their 
assessment of the potential relatedness of each AE to protocol procedure orinvest igational 
product via eCRF .
The invest igator will decide whether he or she interprets the observed AEs as reasonably 
possibly  related to migraine headache, to the investigat ional product, investigational study  
device, study  procedure, or other concomitant treatment or pathologies.
The invest igator will answer y es/no when making this assessment.
Planned surg eries and nonsurgical intervent ions should not be reported as AEs unless the 
underlying medical condit ion has worsened during the course of the study .
If a patient’s investigational product is discontinued as a result of an AE, study  site personnel  
must re port this to Lilly or its designee via eCRF , clarifying if possible, the circumstances 
leading to discontinuati onsof treatm ent.
8.2.1. Serious Adverse Events
An SAE is any  AE from this study  that resul ts in one of the fo llowing outcom es:
death
initial or prolonged inpatient hospitalizat ion
a life -threatening experience (that is, immediate risk of dying)
persistent or significant disabilit y/incapacit y
I5Q-MC-CGAJ Clinical Protocol Page 31
LY2951742congenital ano maly/birth defect
considered significant by  the invest igator for any other reason:  important medical 
events that may  not resul t in death, be life -threatening, or require hospitalization 
may be considered serious, based upon appropriate medical judgment.
when a condit ion related to the invest igational device ( for example, prefilled 
syringeor auto injector ) necessitates medical or surgical intervent ion to precl ude 
either perm anent impai rment of  a body  function or permanent damage to a body  
structure, the seri ous outcom e of “requi red intervent ion” will be assigned.
Although all AEs after signing the ICF are recorded in the eCRF, SAE reporti ng begins after the 
patient has signed the ICF and has received investigational product.  However, if an SAE occurs 
after si gning the ICF, but prior to receiving investigational product, it needs to be reported 
ONLY if it is considered reasonably possibly related to study  procedure.
Study  site personnel  must al ert Lilly or i ts desi gnee of  any SAE within 24 hours of invest igator 
awareness o f the event via a sponsor -approved method.  If alerts are issued via telephone, they 
are to be immediately fo llowed wi th official  notificati on on study -specific SAE forms.  This 24 -
hour notificat ion requirement refers to the init ial SAE informat ion and all fo llow -up SAE 
inform ation.
Pregnancy (during maternal or paternal exposure to invest igational product) does not meet the 
definit ion of an AE.  However, to fulfill regulatory requirements ,any pregnancy that occurs 
during the study , including those in which conceptio n occurred within 5 months after last 
administration of invest igational product, should be reported using the SAE process to collect 
data on the outcome for both mother and fetus.
Invest igators are not obligated to actively seek AEs or SAEs in patients once they  have 
discontinued and/or completed the study  (the patientsummar y eCRF has been com pleted).  
However, if the invest igator learns of any SAE, including a death, at any time after a patienthas 
been discharged from the study , and he/she considers the event reasonably  possibly  related to the 
study  treatm ent or study  participat ion, the invest igator m ust prom ptly notify Lilly .
8.2.1.1. Suspected Unexpected Serious Adverse Reactions
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed 
in the IB and that the investigator ident ifies as relat ed to investigational product or procedure.  
United States 21 CFR 312.32 and European Unio n Clinical Trial Direct ive 2001/20/EC and the 
associ ated detailed guidances or nati onal regulatory  requirements in parti cipat ing countries 
requi re the reporting of SUSARs . Lilly has procedures that will be fo llowed for the recording 
and expedited reporting of SUSARs that are consistent with glo bal regulat ions and the associated 
detailed guidances.
8.2.1.2. Adverse Event Monitoring with a Systematic Questionnaire 
Suicidali tywill be assessed as requi red by the US Food and Drug Administration’s Divisio n of 
Neurol ogy for use in clinical trials invo lving all drugs for neurological indicat ions.  Before 
administering the C-SSRS (Posner et al. 2011 ), study  site personnel  will quest ion the patient 
I5Q-MC-CGAJ Clinical Protocol Page 32
LY2951742about any  change in the pre-exist ing condit ion(s) and the occurrence and nature of any AEs.  
Nonserious AEs obtained through the questionnaire are recorded and analyzed separately. Only 
serious AEs and AEs leading to discont inuat ion elici ted through the C -SSRS are to be recorded 
as AEs via eCRF. Serious adverse events must be reported to Lilly  or its designee wi thin 
24hours as SAEs.   Any suicidal behavior, or suicidal ideat ion per items 4 or 5 (active suicidal 
ideat ion with som e intent to act, either without specific plan or with specific plan and intent) 
woul d prom pt ref erral of the pati ent to a m ental  health prof essional.
8.2.2. Complaint Handling
Lilly co llects product complaints on invest igational products and drug delivery systems used in 
clinical studies in order to ensure the safet y of study  parti cipants, m onitor quali ty, and to 
facilitate process and product improvements.
Patients will  be instructed to contact the investigator as soon as possible if he or she has a 
complaint or probl em wi th the invest igational product (or drug delivery  system such as a 
prefilled syringe orautoinjector ) so that the situation can be assessed.
8.3. Treatment of Overdose
No data are available at this stage of development.
8.4. Safety Assessments
8.4.1. Electrocardiograms
For each patient, a single, 12 -lead digital ECG willbe collected at the visits shown in the 
Schedule of Activities(Appendix 2 ). Electrocardi ogram s will have a central overread and 
shoul d be recorded according to the study -specific recommendat ionsincluded in an ECG
manual.   
Any clinically  significant findings from ECGs that result in a diagnosis should be reported to 
Lilly or i ts desi gnee as an AE viaeCRF .
8.4.2. Vital Signs
Vital signs will  include body  temperature, bl ood pressure, and pulse.  Blood pressure and pulse 
will be measured in triplicate in the sitt ing posit ion prior to bl ood draws and study drug 
administration (seeStudy  Schedule [ Appendix 2 ]).
Any clinically  significant findings from vital signs measurement that result in a diagnosis should 
be reported to Lilly or its designe e as an AE viaeCRF .
8.4.3. Laboratory Tests
For each patient, laboratory testsdetailed in Appendix 3 shoul d be conducted accordi ng to the 
Schedule of Activities (Appendix 2 ). 
Any clin ically  significant findings from laboratory tests that resul t in a di agnosis shoul d be 
reported to Lilly  or its designee as an AE via eCRF .
I5Q-MC-CGAJ Clinical Protocol Page 33
LY2951742In addit ion, an immunogenicit y plasma sample will be collected, when possible, for any  patient 
who experiences a potenti al systemic allergic/hypersensit ivity react ion during the study  as 
judged by  the invest igator. This immunogenicit y plasma sample shoul d be co llected 
immediately  or as soon as possible, taking into consideration the availabilit y and wellbeing o f 
thepatient. Exact date and time of the sample should be recorded on the laboratory requisit ion 
form.
8.4.4. Other Tests 
Not applicable.
8.4.5. Safety Monitoring
Invest igators are responsible for monitoring individual pat ient safety  throughout the tri al.If a 
study  patient/subject experiences elevated ALT ≥3X ULN, ALP ≥2X ULN, or elevated TBL 
≥2X ULN, clinical and laboratory  monitoring should be init iated by  the invest igator. Details for 
hepat ic monitoring depend upon the severit y and persistence of observed laboratory test 
abnorm alities.To ensure patient/subject safet y and com ply wit h regulatory  guidance, the 
investigator is to consult with the Lilly CRP/CRS regarding collect ion of specific reco mmended 
clinical informat ion and fo llow-up laboratory  tests. See Appendix 4 .
Lilly will periodically  review evolving aggregate safet y data wi thin the study . In addit ion, safet y 
data for the trial will also be reviewed periodically  by an independent Data Monitoring 
Committee ( DMC; an advisory  group for the LY2951742 clinical development program) .
8.5. Pharmacokinetics
At the visit s and t imes specified in the Schedule of Act ivities (Appendix 2 ), venous blood
samples of approximately 2.5 mL each will be collected to determine the serum concentrati ons 
of LY2951742 .  A maximum o f 3 sam ples m ay be collected at addi tional time points during the 
study  if warranted and agreed upon between both the investigator and sponsor.  Instructions for 
the collect ion and handling of blood samples will be provided by the sponsor.   
When a blood sample is collected , the time and date of l ast dose administration prior to blood 
sampling should be recorded .  The actual date and time (24-hour clock time )of each sampling 
will be recorded.   Bioanaly tical samples collected to measure invest igational product 
concentration will be re tained for a maximum of 1 year fo llowing l ast pati ent visi t for the study .
A validated assay will be used to determine serum LY 2951742 concentrations.  Samples will be 
analyzed at a laboratory  approved by  the sponsor.  
8.6. Pharmacodynamics
At the visit s and t imes specified in the Schedule of Act ivities (Appendix 2 ), venous blood 
samples will be co llected to determine the plasma concentrations of CGRP.  A maximum o f 
3samples m ay be collected at addit ional time points during the study if warranted and a greed 
upon between both the investigator and sponsor.  Instructions for the collection and handling o f 
blood sam ples will  be provi ded by the sponsor.  When a blood sample is collected , the time and 
I5Q-MC-CGAJ Clinical Protocol Page 34
LY2951742date of l ast dose administration prior to blood sampling s hould be recorded .  The actual date and 
time (24-hour clock time )of each sampling will be recorded.
A validated assay will be used to determine plasma drug- tolerant CGRP concentrations.  
Samples will  be analyzed at a l aboratory  approved by  the sponsor.
Bioanalyt ical samples collected to m easure CGRP will be ident ified by the patient number 
(coded) and retained for a maximum o f 1 year following last patient visit for the study  at a 
facilit y selected by  the sponsor.
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
8.8. Biomarkers
Blood samples for non -genet ic biomarker research will be co llected at the times specified in t he 
Schedule of Act ivities (Appendix 2 ),where local regulat ions and ERBs allow.
Samples will  be used for research on the drug target, disease proce ss, pathways associated with 
migraine headache and/or other pain condit ions, mechanism  of action of LY2951742, and/or 
research method or in validat ing diagnost ic tools or assay(s) related to migraine headache and/or 
other pain condit ions.  
CCI
I5Q-MC-CGAJ Clinical Protocol Page 35
LY2951742All biomarker samples will be coded with the patient number.  These samples and any  data 
generated can be linked back to the patient only by the investigator site personnel.  Samples will 
be destroy ed according to a process consistent with local regulat ions.
Samples wil l be retained for a maximum 15 years after the last patient visit for the study , or f or a 
shorter period if local regulat ions and ERBs impose shorter time limits, at a facilit y selected by  
the sponsor.   This retent ion peri od enables use o f new techno logies, response to regul atory  
questions, and invest igation of variable response that may not be observed unt il later in drug 
development or when the drug is commercially available.
8.8.1. Samples for Immunogenicity Research
Where local regulat ions and ERBs allow, bloo d samples for immunogenicit y testing will be 
collected to determine ant ibody  producti on against LY2951742 as specified in the Schedule of 
Activities (Appendix 2 ).Immunogenicit y will be assessed by a validated assay designed to 
detect anti -drug ant ibodies in the presence o f the investigational product.  Ant ibodies may be 
further characterized and/or evaluated for their abilit y to neutralize the activ ity of LY2951742.
Samples will  be retained for a m aximum  of 15 y ears after the last patient visit for the study , or 
for a shorter peri od if regulat ions and ERBs impose shorter time limits, at a facilit y selected by  
the sponsor.  The duration allows the spo nsor to respond to future regulatory requests related to 
LY2951742.
8.9. Health Economics
The self -reported questionnaires will be administered according to the Schedule o f Activities
(Appendix 2 ).  Health economic, disabilit y and quali tyof life assessments of LY2951742 in 
patients wi th migraine will be based on the following scales:
Migraine Disability Assessment test (M IDAS ): The MIDAS was designed to quantify 
headache -related di sabili ty over a 3 -month peri od.  Thi s instrum ent consists of five items that 
reflect the number of days reported as missing, or with reduced productivit y at work or hom e and 
social events, are wei ghted to p roduce scores in which a higher value is indicat ive of more 
disabili ty (Stewart 1999 ;Stewart 2001 ).  This instrument is considered highly reliable and valid; 
and is correlated with clinical judgment regarding the need for medical care (Stewart 1999 ;
Stewa rt 2001) . 
Migraine Specific Quality of Life questionnaire (MSQ v2.1): The MSQ v2.1 i s a self-
administered healt h status instrument, and was developed to address physical and emotional 
limitations of specific concern to individuals suffering fro m migraine headaches. The instrument 
consists of 14 items that address 3 dom ains: (1) Role Functi on-Restrictive ;(2) Rol eFuncti on-
Preventive; and, (3) Emotional Funct ion (Jhingran 1998) .  The instrument was designed with a 4 -
week recall period, and is considered r eliable, valid and sensit ive to change in migraine ( Jhingran 
1998; Rendas -Baum 2013 ). Clinically meaningful differences for each domain have been 
established and are widely used in the literature.
I5Q-MC-CGAJ Clinical Protocol Page 36
LY2951742Patient Satisfaction with Medication Questionnaire Modifi ed(PSMQ -M):The PSMQ -Mis 
a self-rated scale which measures patient s’level of satisfact ion withstudy  medicat ion(Kalali
1999 ). The scale has been modified for use in this study , assessing 3 items related to the clinical 
trial treatm ent over the past 4 weeks: satisfact ion, preference, and side effects. Satisfact ion 
responses range fro m “very unsat isfied” to “very  satisfied” wi th the current treatment. 
Preference compares the current study  medicat ion to previ ous m edicat ions, wi th responses fro m 
“much rather prefer my previ ous medicat ion” to “much rather prefer themedicationadministered 
to me during the study .”
Health Care Resource Utilization (HCRU) and Employment Status :The HCRU will be 
solicit ed by  study  personnel while document ing patient responses. The HCRU consists o f 3 
questions, asking about hospi talemergency room visits, overnight stays in a hospital, and any 
other visits with a healt hcare professional that occurred since their last stu dy visit. Patients are 
also specifically asked about the number of healt h care events that are related to migraine 
headaches, outside of visits associated with their participat ion in the clinical trial. The baseline 
visit will include the same quest ions, however with the frame of reference being over the last 6 
months.  A quest ion on employment status is also solicited, given the correlat ion and potential 
confoundi ng wi th health outcom es measures . 
Subcut aneous Administration Assessment Questionnaire (SQAAQ ):  The SQAAQ is a self-
administered questionnaire that provides an assessment of ease of use and confidence wit h using 
a device to administer a subcutaneous inject ion of investigat ional product .  Patien ts will respond 
to questi onnaire i tems using a 7 -point Li kert scal e (fro m “Strongly Disagree” to “Strongly 
Agree”) shortly after the injection . If a caregiver administer sthe injection, the patient should be 
prepared to provide the caregiver’s ratings of the questions.
I5Q-MC-CGAJ Clinical Protocol Page 37
LY29517429.Statistical Considerations and Data A nalysis
9.1. Determination of Sample Size
Approximately  250 pati ents will be enrolled in Study  CGAJ.  This sample size will ensure at 
least 100 patients with at least 1 y ear of  exposure to fulfill regulatory  requirements for 
registrati on.
9.2. General Statistical Considerations
Statistical analysis o f this study  will be the responsibilit y of Lilly or its desi gnee.   Details o f 
statist ical analysis methods will be described in the statist ical analysis plan (SAP) document.
Unless otherwise specified, safety and effect iveness analyses will be conducted on an intent -to-
treat (ITT) basis, which is to include all pat ientswho receive at least one dose of invest igational 
product. When change from baseline is assessed, the pat ient will be included in the analysis only 
if he/she has a baseline and a post -baseline measurement.
All statistical tests will be conducted at a 2 -sided alpha level o f 0.05, and 95% confidence 
intervals will be provi ded if appropri ate, unless otherwise stated. No adjust ments for multiplicity 
willbe applied to any  safet y or efficacy  analyses.
Continuous safety  and efficacy  variables with repeated m easures will be analyzed using mixed-
model repeated m easures (MMRM) which will include the fixed categorical effects of treatm ent, 
treatm ent-by-visit interaction, pooled investi gative site, visit, as well as the continuous fixed 
covari ates of baseline and baseline -by-visit interacti on.
The safet yand efficacy analys es will  be conducted for Study  Period IIandStudy Period III
(post-treatment follow -up phase ), as well as the two periods combined.
When appropriate ,an analysis of variance (ANOVA) or an analysis of covariance ( ANCOVA )
model with last-observat ion-carried -forward ( LOCF )imputation will be used.  Unless otherwise 
specified, when an ANOVA modelis used to analyze a cont inuous variable, the model will 
contain the main effect of treatm entand pooled investigative site. When an ANCOVA model is 
used to analyze change fro m baseline for a continuous variable, the model will include treatm ent,
baseline ,and pooled investigative site.
Categorical variables wit h repeated measures will be summarized and analyzed in a similar 
manner as for mean change sfrom a categorical, pseudo li kelihood -based repeated measures 
analysis using a generalized linear mixed model ( GLIMMIX ) procedure in SAS. Categorical 
variables wit hout repeated measures will be analyzed by Cochran -Mantel -Haenszel (CMH) test 
controlling for pooled invest igative site (Fisher ’s exact tests, if needed). 
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the p rotocol .  Any  other change to the data analysis 
methods described in the protocol, and the just ification for making the change, will be described 
in the clinical study  report (CSR) .  Additional exploratory analyses of the data will be conducted 
as deemed a ppropri ate.
I5Q-MC-CGAJ Clinical Protocol Page 38
LY29517429.3. Treatment Group Comparability
9.3.1. Patient Disposition
The number and percentage of ITT patients who complete the study or discontinue early will be 
summariz ed for the open -label treatment phase ( Study  Period II)and post-treatment follow -up 
phase ( Study  Period III )both overall and by visit. 
9.3.2. Patient Characteristics
The fo llowing pati ent characteri stics at baseline will be summarized for all ITT patients.
Dem ographic (age, gender, ethnic origin, height, weight, body mass index )
Migraine headache, headache 
Medical history  and pre-exist ing condit ion 
Medical history and pre -exist ing condit ions will be summarized by preferred term within system  
organ class (SOC).
9.3.3. Concomitant Therapy
The proporti on of  patients who received conco mitant medicat ion collected via eCRF will be 
summarized for all ITT pati ents f or the open -label treatment phase and post-treatm ent follow-up 
phase separately .
9.3.4. Treatment Compliance
Number of missed inject ions will be summarized.
9.4. Primary  and Secondar y Anal yses
9.4.1. Primary Analyses
The primary  object ive of this study  is to eval uate the l ong -term safet y and tol erabilit y of 
LY2951742 (120 or 240 mg/month)in pat ients suffering fro m migraine, with or without aura, for 
up to 1 year of treatment.
The safet y and tol erabil ity of treatm ent will be assessed by  summarizing the following:
adverse event s
otreatm ent-emergent adverse events
by preferred term
by SOC
by maximum severit y 
considered to be related to investigat ional product by invest igator
oseriousadverse events
I5Q-MC-CGAJ Clinical Protocol Page 39
LY2951742oadverse event leading to discont inuat ion
suicidal ideation and behaviors assessed by so licited questioning using the C -
SSRS
vital signs and wei ght
electrocardi ogram s
laboratory  measurements
anti-LY2951742 antibody
9.4.2. Secondary Analyses
9.4.2.1. Efficacy Analyses
The efficacy object ive is to evaluate the effect iveness of LY2951742 in the prevent ion of 
migraine , using the fo llowing measures: 
mean change fro m baseline in the number of migraine headache days
mean change fro m baseline in the number of headache days
the proporti on of  patients m eeting cri teria for reducti ons of  at least 30%, 50%, 
75%, or 100% in the number of migraine headache days
mean change fro m baseline in the frequency  of medication use for the acute 
treatm ent of migraines or headaches
mean change from baseline in pat ient’s glo bal impressio n of illness as measured 
by PGI -Severi ty 
patient’s gl obal impressi on of  improvement as measured by PGI -Improvement 
post-baseline
time to first loss of response (when patient no longer meets 50% response criteria 
and/or starts treatment using migraine prevention medicat ion) during the fo llow-
up phase
For migraine headache and headache day analysis, baseline is the Visit 2 assessment.
9.4.3. Tertiary/Exploratory Analyses
Not applicable.
9.5. Other Safety Analyses
9.5.1. Immunogenicity Analyses
To evaluate the changes in immunogenicit y data ( anti-drug ant ibodies , neutralizing anti-drug 
antibodies ) after treatment, the following statistical analyses are planned:
to summarize the proportions of posit ive results at each sample collection t ime 
point. 
I5Q-MC-CGAJ Clinical Protocol Page 40
LY2951742to summarize the incidence of treatment -emergent immunogenicit y for the open -
label treatment phase.  Treatment -emergent immunogenicit y will be defined as 
any of the fo llowing:
oa negat ive baseline result and a posit ive postbaseline anti-drug ant ibody resul t 
with a titer ≥20. This is also called treatment -induced ADA. 
oa posi tive baseline result and a posit ive postbaseline anti-drug antibody resul t 
with a ≥4-fold increase in t iters (for example, baseline titer of 10 increasing to 
≥40 postbaseline).   This is called treatment -boosted ADA.
to summarize the onset of treatment -induced anti-drug antibody . Anti-drug 
antibody onset is defined as the time period between the init ial administration of 
the study  drug and the first instance of tre atment-induced ADA .
LY2951742 and CGRP concentrations will be illustrated graphically and summarized 
descript ively.   
 
 
 
 
9.7. Other Analyses
9.7.1. Health Outcomes and Economic s
The m ean change from  baseline to each postbaseline visit for open -label treatme nt phase for 
MSQv2.1 (including Role Funct ion-Restri ctive, Role Function -Prevent ive, Emotional Functi on,
andtotal score )andMIDAS (item scores and total  score )(Section 8.9)will be summari zedusing 
MMRM as described in Sect ion9.2.
The HCRU and PSMQ -M will be analyzed with details documented in the SAP. 
9.7.2. Device Analyses
Evaluat ion of autoinjector and prefilled syringe ease of use using the SQAAQ quest ionnaire will 
be summarized and analyzed for each individual it em and/or dom ains.  In addit ion, autoinjector 
exposures will be evaluated with respect to inject ion-related events and device performance.  
Further details will be in the SAP.
9.8. Subgroup Analyses
Subgroup analyses will be conducted on key  safet y measures for the fo llowing variables:
sex (Female v ersus Male)
baseline anti-drug ant ibody status : Any confirmed posit ive anti-drug ant ibody at 
baseline (Yes v ersus No)
CCI
CCI
I5Q-MC-CGAJ Clinical Protocol Page 41
LY2951742treatment -emergent anti-drug antibody status : Any treatment -emergent anti-drug 
antibody (Yes v ersus No)
neutralizing anti-drug ant ibody status:  Any posit ive neutralizing ADA t ime point 
(Yes v ersus No) –note that neutralizing anti-drug ant ibody assays are performed 
only on confi rmed-positive anti-drug antibodies .
Region: North American, Europe, Other 
Disease state: epi sodic migraine versus chronic migraine
Medicat ion overuse headache: Yes versus No
Subgroup analyses for additional variables will be conducted as deemed appropriate and 
necessary . Detailed descript ion of the subgroup variables will be provided in the SAP. 
9.9. Interim Analyses
No interim analyses are planned for this study .  However, an interim analysis may be conducted 
in support of regulatory  submissi ons if necessary .  Interim data snapshots will be provided as 
supplemental  safety  data to support external DMC safet y reviews across all Phase 3 migraine 
prevent ion studi es.
I5Q-MC-CGAJ Clinical Protocol Page 42
LY295174210.Study  Governance Consi derations
10.1. Regulatory and Ethical Considerations, Including the Informed 
Consent Process
10.1.1. Informed Consen t
The invest igator is responsible for ensuring:
that the patient understands the potential risks and benefits of part icipating in the 
study
that informed consent is given by  each patient.  This includes obtaining the 
appropriate signatures and dates on the ICF prior to the performance of any 
protocol  procedures and prior to the administration of invest igational product.
answering any quest ions the pati ent may have throughout the study  and sharing in 
a timely manner any  new informat ion that m ay be rel evant to the pati ent’s 
willingness to continue his or her participat ion in the trial.
10.1.2. Ethical Review
The invest igator must give assurance that the ERB was properly const ituted and convened as 
requi red by Internat ional Conference on Harmonisation (ICH) guidelines and other applicable 
laws and regulations.
Docum entati on of  ERB approval  of the protocol and t he ICF must be provided to Lilly before the 
study  may begin at the investi gative si te(s).  Lilly  or its representatives must approve the ICF, 
including any  changes made by the ERBs, before it is used at the invest igative site(s).  All ICFs
must be complian t with the ICH gui deline on good clinical pract ice (GCP ).
The study  site’s ERB(s) shoul d be provided wi th the f ollowing:
the current IB and updates during the course of the study
inform ed consent form
relevant curri cula vi tae
10.1.3. Regulatory Considerations
This study  will be conducted in accordance wit h:
consensus ethics principles derived fro m internat ional ethics guidelines, including 
the Decl aration of Helsinki and Council for International Organizations of 
Medical Sciences (CIOMS) International Ethical Guidelines
applicable ICH GCP guideline s
applicable laws and regulations
Some of the obligat ions of the sponsor will be assigned to a third-party organi zation (TPO) .
I5Q-MC-CGAJ Clinical Protocol Page 43
LY295174210.1.4. Investigator Information
Invest igators in this clinical trial should be neuro logists, head ache specialists, or other specialists 
with experi ence in headache clinical trials and treating migraine headache pat ients.
10.1.5. Protocol Signatures
The sponsor’s responsible medical o fficer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study .
After reading the protocol, each principal invest igator will sign the protocol signature page and 
send a copy  of the signed page to a Lilly representative.
10.1.6. Final Repo rt Signature
The CSR coordinat ing invest igator will sign the final CSR for this study , indicating agreement 
that, to the best of his or her knowledge, the report accurately describes the conduct and results 
of the study .
An invest igator selected by  the stu dy team  will serve as the CSR coordinat ing invest igator.  If 
this invest igator is unable to fulfill this funct ion, another invest igator will be chosen by Lilly to 
serve as the CSR coordi nating invest igator.
The sponsor’s responsible medical o fficer and sta tistician will approve the final CSR for this 
study , confirming that, to the best of his or her knowledge, the report accurately describes the 
conduct and results of the study .
10.2. Data Quality Assurance
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the fo llowing:
provi de instructi onal materi al to the study  sites, as appropriate
sponsor start -up training to instruct the invest igators and study  coordinators.  This 
training will give instructi on on the protocol, the complet ion of the eCRFs, and 
study  procedures .
make periodic visit s to the study  site
be available for consultation and stay  in contact with the study  site personnel by  
mail, tel ephone, and/or fax
review and eval uate eCRF data and use standard computer edits to detect errors in 
data collect ion
conduct a qualit y review of the database
In addit ion, Lilly or its representatives willperiodically check a sample of the patient data
recorded against source documents at the study  site.  The study  may be audi ted by  Lilly or i ts 
representatives ,and/or by regul atory  agencies at any  time.  Invest igators will be given notice 
before an audit occurs.
I5Q-MC-CGAJ Clinical Protocol Page 44
LY2951742To ensure the safet y of parti cipants in the study , and to ensure accurate, com plete, and reliable
data, the invest igator will keep records of ECGs, laboratory tests, clinical notes, and patient
medical records in the patient files as original source documents for the study  according to 
retenti on requi rements as outlined by the ICH g uidelines. If requested, the investigator will 
provi de the sponsor, applicable regulatory  agencies, and applicable ERBs with direct access to 
original  source docum ents.
10.2.1. Data Capture System
An electronic data capture sy stem will be used in this study .  The site maintains a separate source 
for the data entered by  the si te into the sponsor -provided electronic data capture system.
Some or all  of a patient’s data will be direct ly entered into the eCRF at the time that the
information is obtained. In instances where di rect data ent ry is not used , the si te will maintain 
source documentation in the trial files ,and the patient ’s data will be transcribed into the eCRF.
Any data for which the eCRF will serve as the source document, or any  other data not entered 
directly into the eCRF, will be ident ified and documented by the site in the site ’s trial file. For 
data handled by  a data management TPO, eCRF data and some or all data that are related will be 
managed and stored electronically in the TPO system. Subseque nt to the final database lock, 
validated data will be transferred to the sponsor. For data handled internally, eCRF data and 
some or all data that are related will be managed by the sponsor and stored electronically in the 
sponsor ’s system .
In thi s study ,patient-rated scales/quest ionnaires will be co llected at office visits directly via an 
electronic pat ient-reported outcome (e PRO )tablet device as part of an ePRO/Clinical Outcome 
Assessment (COA) system. Data entered into the ePRO/COA system will serve as the source 
data.
If ePRO/ COA records are stored at a third -party  site, investigator sites will have continuous 
access to the source documents during the study  and will receive an archival copy  at the end of 
the study  for retenti on.
Any data for which th e ePRO/ COA instrum ent record will serve to collect source data will be 
ident ified and documented by each site in that site’s study file.
Case report form data will be encoded and stored in a clinical trial database.  Data managed by a 
central  vendor, such as laboratory  test data or ECG data, will be stored electronically in the 
central  vendor’s database system.  Data will subsequent ly be transferred from the central vendor 
to the Lilly data warehouse . Data from complaint forms submitted to Lilly will be en coded and 
stored in the global product complaint management sy stem.
I5Q-MC-CGAJ Clinical Protocol Page 45
LY295174210.3. Study and Site Closure
10.3.1. Discontinuation of Study Sites
Study  site parti cipat ion may be discont inued if Lilly  or its desi gnee , theinvest igator, or the ERB 
of the study  sitejudges it necess ary for medical , safet y, regulatory , or other reasons consistent 
with applicable l aws, regul ations, and GCP.
10.3.2. Discontinuation of the Study
The study  will be discontinued if Lilly or its designee judges it necessary  for medical, safet y, 
regul atory , or other reasons consistent with applicable laws, regulat ions, and GCP.
I5Q-MC-CGAJ Clinical Protocol Page 46
LY295174211.References
Goadsby PJ, Edvinsson L. The trigemino vascular system and migraine: studies characteri zing 
cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol . 
1993;33(1):48 -56.
Goadsby  PJ, Edvinsson L, Ekm an R. Vasoactive peptide release in the extracerebral circulat ion 
of humans during migraine headache. Ann Neur ol. 1990;28(2):183 -187.
Guy W. ECDEU assessment manual for psychopharmacology , revised 1976. Rockville, MD: 
National Inst itute of Mental Health, Psychopharmacology  Research Branch. p 217 -222. 
Available at: https://archive.org/details/ecdeuassessmentm1933gu yw. Accessed 27 July 2015 .
[ICHD -3] Headache Classificat ion Co mmittee of the Internat ional Headache Societ y (IHS). The
International Classificat ion of Headache Disorders, 3rd edit ion (beta versio n). Cephalalgia . 
2013;33(9):629 -808.
Jhingra n P, Osterhaus JT , Miller DW, Lee JT, Kirchdoerfer L. Development and validat ion of 
the Migraine-Specific Quality of Life Questi onnai re. Headache .1998;38(4):295 -302.
Kalali A. Pati ent sati sfact ion with, and acceptabilit y of, atypical ant ipsychotics. Curr Med Res 
Opin. 1999;15 (2):135 -137.
Lassen LH , Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play  a 
causat ive role in migraine. Cephalalgia .2002;22(1):54 -61.
Lassen LH, Jacobsen VB , Pedersen PA, Sperling B, Iversen H K, Olesen J. Hum an calci tonin 
gene-related pepti de (hCGRP)- induced headache in migraineurs. Eur J Neurol . 
1998;5(suppl 3):S63.
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin 
GA, Greenhill L, Shen S, Mann JJ. The Co lumbia -Suicide Severi ty Rating Scale: init ial 
validit y and internal  consistency findings from three mult isite studies wit h adolescents and 
adults.Am J Psychiatry . 2011;168(12):1266 -1277.
Rendas -Baum R, Bl oudek LM, Maglinte GA, Varon SF. The psy chometric properti es of the 
Migraine -Speci fic Qualit y of Life Quest ionnaire version 2.1 (MSQ) in chronic migraine 
patients. Qual Life Res .2013;22 (5):1123 –1133.
Rizzoli P. Preventive pharmacotherapy  in migraine. Headache . 2014;54(2):364 -369.
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E. Evidence -based 
guideline update: Pharmaco logic treatm ent for epi sodic migraine prevent ion in adults: Report 
of the Qualit y Standards Subcommittee of the American Academy of Neurology  and the 
American Headache Societ y. Neurol ogy. 2012;78(17):13 37-1345.
Stewart WF, Lipton RB, Dowson AJ, Sawyer J. Development and testing of the Migraine 
Disabili ty Assessment (MIDAS) Questionnaire to assess headache -related di sabili ty. 
Neurology .2001;56 (6 Suppl 1):S20 -S28.
Stewart WF, Lipton RB, Kolodner K, Liberm an J, Sawy er J. Reliabilit y of the migraine 
disabili ty assessment score in a populat ion-based sample of headache sufferers. Cephalalgia .
1999; 19(2):107 -114.
I5Q-MC-CGAJ Clinical Protocol Page 47
LY2951742Villaló n CM, Olesen J. The role of CGRP in the pathophysio logy of migraine and efficacy  of 
CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther . 2009;124(3):309 -
323.
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al. Years lived with 
disabili ty (YLDs) for 1160 sequelae of 289 diseases and injuries 1990 -2010: a sys tematic 
analysis for the Global Burden of Disease Study  2010. Lancet. 2012;380(9859): 2163 -2196.
I5Q-MC-CGAJ Clinical Protocol Page 48
LY2951742Appendix 1. Abbreviations and Definitions
Term Definition
AE adverse event:  Any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product that does not necessarily have a causal 
relatio nship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally  associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product.
complaint A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, pu rity, durability , reliability , safety  or effectiveness, or 
performance of a drug or drug delivery system.
enroll The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are 
those who have been assigned to a treatment.
enter Patients entered into a trial are those who sign the informed consent form .
interim analysis An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/lock ed.
investigational 
productApharmaceutical form of an active ingredient or placebo being tested or used as a 
reference in a clinical trial , including products already on the market when used or 
assembled (formulated or packaged) in a way different from the authorized form, or 
marketed products used for an unauthorized indication, or marketed products used to 
gain further information about the authorized form.
ITT intent to treat : The principle that asserts that the effect of a treatment policy can be best 
assessed by evaluating o n the basis of the intention to treat a patient (that is, the planned 
treatment regimen) rather than the actual treatment given.  It has the consequence t hat 
patients allocated to a treatment group should be followed up, assessed ,and analyzed as 
members of that group irrespective of their compliance to the planned course of 
treatment.
IWRS interactive web -response sy stem
SAE serious adverse event
TEAE treatment -emergent adverse event : Any untoward medical occurrence that either occurs 
or worsens at any time after treatment baseline and thatdoes not necessarily have to 
have a causal relationship with this treatment .
I5Q-MC-CGAJ Clinical Protocol Page 49
LY2951742Appendix 2. Schedule of A ctivities
I5Q-MC-CGAJ Clinical Protocol Page 50
LY2951742Schedule of Activities Protocol I5Q-MC -CGAJ
Study Period (SP) SP I SP II SP III
DescriptionScreen -
ingTreatmentPost-treatment 
Interval (days) since 
previous visit, days3-45 14 16 30 30 30 30 30 30 30 30 30 30 30 60 60 ET
Interval allowance (days) +/- 3 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 5 +/- 5
Visit 1 2 3a 4 5 6 7
(Phone
visit)8
(Phone
visit)910
(Phone
visit)11
(Phone
visit)1213
(Phone
visit)14
(Phone
visit)15 16 17
Month 0 0.5 1 2 3 4 5 6 7 8 9 10 11 12 14 16
Assessments and Procedures
Informed consent X
Inclusion /exclusion X X
Demographics X
Physical examination b X
Height X
Weight X X X X X
Waist /hipcircumference X
Medical history X
Pre-specified 
migraine historyX
Substance use X
ECG c X X X X X X
Vital signs d X X X X X X X X X X X
Adverse events and 
product complaintsX X X X X X X X X X X X X X X X X X
LY2951742 treatment e X X X X X X X X X X X X
Concomitant 
medicationsX X X X X X X X X X X X X X X X X
I5Q-MC-CGAJ Clinical Protocol Page 51
LY2951742Study Period (SP) SP I SP II SP III
DescriptionScreen -
ingTreatmentPost-treatment 
Interval (days) since 
previous visit, days3-45 14 16 30 30 30 30 30 30 30 30 30 30 30 60 60 ET
Interval allowance (days) +/- 3 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 2 +/- 5 +/- 5
Visit 1 2 3a 4 5 6 7
(Phone
visit)8
(Phone
visit)910
(Phone
visit)11
(Phone
visit)1213
(Phone
visit)14
(Phone
visit)15 16 17
Month 0 0.5 1 2 3 4 5 6 7 8 9 10 11 12 14 16
Clinical Laboratory Tests and Sampling Schedule
Hematology X X X X X X X X
Clinical chemistry X X f X Xf X Xf X X f
HDL X X f X Xf X Xf X X f
Urinalysis g X X X X X X
HbA1c X X X X X
Fasting insulin/
fasting C -peptideXf Xf Xf
Serum p regnancy (for 
women of childbearing 
potential) or FSH (Visit 
1 only; all other female 
patients)X X X X
Urine pregnancy h X X X X X X X X X X X X
Urine drug screen X
Immunogenicity i X X X X X X X X X
PK blood sample i X X X X X X X X
Biomarker storage 
sample iX X X X X X X
CCI
CCI
I5Q-MC-CGAJ Clinical Protocol Page 52
LY2951742Scales, Questionnaires, and Outcomes Measures
Assessment of migraine 
and h eadache daysX X X X X X X X X X X X X X X X
MIDAS X X X X X X X
MSQ (v2.1) X X X X X X X X X X
HCRU and Employment
StatusX X X X X X X X X X X X X X X X
PSMQ -M X X X X
PGI-Severity X
PGI-Improvement X X X X X X X
Nonmigraine chronic 
pain assessment jX X X X
SQAAQ X X X X X X X X X X X X X
C-SSRS/SHSF, SHFU k X X X X X X X X X X X X X X X X X
I5Q-MC-CGAJ Clinical Protocol Page 53
LY2951742Schedule of Activities Protocol I5Q-MC -CGAJ (abbreviations and footnotes)
Abbreviations:  AE = adverse event; CGRP = Calcitonin -gene related peptide; C-SSRS = Columbia -Suicide Severity Rating Scale ; ECG = electrocardiogram; ET = early termination; FSH = follicle 
stimulating hormone; HbA1c = hemoglobin A1c ;  HCRU = Health Care Resource Utilization; HDL = High-density lipoprotein ;MIDAS = Migraine Disability Assessment test ; MSQ (v2.1) = 
Migraine Specific Quality of Life Questionnaire Version 2.1 ; PGI = Patient Global Impression ;PK = pharmacokinetics; PSMQ -M = Patient Satisfaction with Medication Questionnaire -Modified ; 
SHSF = self-harm supplement form; SHFU = self-harm follow -up form ;SQAAQ = Subcutaneous Administration Assessment Questionnaire .
Note: S elected tests may be obtained in the event of a treatment -emergent hepatic abnormality and may be required in follow- up with patients in consultation with the Lilly, or its designee, cli nical 
research physician .  If the patient has discontinued the trial and returns for hepatic follow -up, the site should use the 800 series as the visit designation.
aVisit 3 will be for collection of PK, immunogenicity, and CGRP plasma samples and spontaneously reported AE s.
bPhysical examinations at screening must include a neurological exam.
cElectrocardiograms ( ECG s)will be performed at Visit 1, Visit 2, Visit 9, Visit 15 and Visit 17 or early termination .  Note:  the Visit 2ECG should be co llected prior to blood draws and dosing.  
Patients must be supine for approximately 5 to 10 minutes before ECG collection and remain supine but awake during ECG collec tion. 
dVital signs will include body temperature, blood pressure, and pulse.  Blood pre ssure and pulse will be measured in triplicate in the sitting position and should be measured prior to blood draws.  
Blood pressure will be assessed by utilizing a calibrated machine .
ePatients will receive injections ofLY2951742 after all other visit p rocedures are completed.  Following the first dose at Visit 2, patients will be observed for at least 30 minutes in the office.
Injections administered by the patient at Visit 4 and Visit 5 will be done in the office under the supervision of the staff; all subsequent injections will be administered by the patient/caregiver and 
should be unsupervised by the clinical staff.
fFastin g laboratory samples (such as chemistry) will be collected at baseline (Visit 2), 6 months (Visit 9), and study endpoint (Visit 15 or early study termination ).  Fasting status is defined as no food 
or caloric beverage 8 hours prior to testing .  All other s amples may be collected on a nonfasting basis.
gIn the event of a positive urine leukocyte esterase result, a repeat urine sample will be collecte d and shipped to the central laboratory.
hA positive urine test must be followed by a serum pregnancy test for confirmation. Patients will be provided with a home pregnancy kit for testing (prior to injection) at each home visit.
iImmunogenicity,  and biomarker storage sample s, as well as PKblood sampling to be performed at the indicated visits an d prior to dose administration if the visit is a dosing visit.  
Samples will be taken in the event of early termination. Immunogenicity samples also willbe collected in the event of a potential systemic allergic/hypersensitivity reaction (see Section 8.4. 3).The 
exact date and time of the sample should be recorded. 
jQuestionnaire administered by clinician to assess other chronic pain conditions.
kThe C -SSRS, and SHSF (and SHFU when applicable) will be completed at scheduled and unscheduled office visits.
CCI
I5Q-MC-CGAJ Clinical Protocol Page 54
LY2951742Appendix 3. Clinical Laboratory  Tests
Clinical Laboratory Tests
Hematology : Clinical Chemistry:b
Hemoglobin Serum Concentrations of:
Hematocrit Sodium
Erythrocy te count (RBC) Potassium
Mean cell volume Total bilirubin
Mean cell hemoglobin concentration Direct bilirubin
Leukocytes (WBC) Alkaline phosphatase
Neutrophils, segmented Alanine aminotransferase (ALT)
Lymphocy tes Aspartate aminotransferase (AST)
Monocytes Blood urea nitrogen (BUN)
Eosinophils Creatinine
Basophils Uric acid
Platelets
HbA 1cCalcium
Glucose (fasting )b
Urinalysis :
Specific gravity
pH
Protein
Glucose
KetonesAlbumin
Creatine kinase (CK)
Triglycerides
Total cholesterolb
HDLb
Blood
Urine leukocyte esterasea
Microscopic analysisa
Urine cultureaFasting insulinb
Fasting C-peptideb
Other
Plasma (drug -tolerant CGRP)
PK Sample (LY2951742 serum concentration 
determination)
Immunogenicity
Urine Drug Screenc
Pregnancy Test (females only)d
Serum pregnancy or FSH
Urine pregnancy
Stored Samples
Biomarker Storage 
Abbreviations:  CGRP = calcito nin gene -related peptide ; FSH = follicle -stimulating hormone; HbA1c = hemoglobin 
A1c; HDL = high density lipoprotein; PK = pharmacokinetic; RBC = red blood cells; WBC = white blood cells.
CCI
I5Q-MC-CGAJ Clinical Protocol Page 55
LY2951742Clinical Laboratory Tests (footnotes)
aA positive urine leukocyte esterase result will require a follow -up sample with microscopic analysis and possibly 
a urine culture.
bFasting laboratory samples will be collected as shown in the Schedule of Activities (Appendix 2).  Fasting is 
defined as no food or drink, except water, for at least 8 hours prior to testing.  All other samples may be collected 
on a no nfasting basis.
cMaybe repeated during the study at the discretion of the investigator.
dMay be repeated during the study at the discretion of the investigator .
I5Q-MC-CGAJ Clinical Protocol Page 56
LY2951742Appendix 4. Hepatic Monitoring Tests for Treatment -
Emergent A bnormality
Selected tests m ay be obtained in the event of a treatment -emergent hepatic abnormalit y and may  
be required in fo llow-up wi th patients in consultat ion with the Lilly , or i ts desi gnee, clinical 
research physician.
Hepatic Monitoring Tests
Hepatic Hematology a Haptoglobin a
Hemoglobin
Hematocrit Hepatic Coagulation a
RBC Prothrombin Time
WBC Prothrombin Time, INR
Neutrophils, segmented
Lymphocy tes Hepatic Serologies a,b
Monocytes Hepatitis A antibody, total
Eosinophils Hepatitis A antibody, IgM
Basophils Hepatitis B surface antigen
Platelets Hepatitis B surface antibody
Hepatitis B Core antibody
Hepatic Chemistry a Hepatitis C antibody
Total bilirubin Hepatitis E antibody, IgG
Direct bilirubin Hepatitis E antibody, IgM
Alkaline phosphatase
ALT Anti -nuclear antibody a
AST
GGT
CPKAlkaline phosphatase isoenzymes a
Anti -Actin antibody a
Anti -smooth muscle antibody a
Abbreviations:  ALT = alanine aminotransferase; AST = aspirate aminotransferase; CPK = creatinine 
phosphokinase; GGT = gamma -glutamyl transferase; Ig = immunoglobulin; INR = international normali zed 
ratio; RBC = red blood cells; WBC = white blood cells.
aAssay ed by Lilly -designated or local laboratory.
bReflex/confirmation dependent on regulatory requirements and/or testing availability .
Leo Document ID = f01eefab-cb1d-41be-ba01-8458440c4552
Approver: 
Approval Date & Time: 23-Sep-2015 19:08:51 GMT
Signature meaning: Approved
Approver: 
Approval Date & Time: 23-Sep-2015 20:07:55 GMT
Signature meaning: Approved
PPD
PPD